AACR: Novel COVID-19 Vaccine Aimed at Immunocompromised Patients
THURSDAY, April 21, 2022 (HealthDay News) -- Interim results of early research show that a new vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), CoVac-1, induces T-cell immune responses in 93 percent of patients with B-cell deficiencies, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 8 to 13 in New Orleans.
Claudia Tandler, from University Hospital Tübingen in Germany, and colleagues presented the interim safety and immunogenicity results of a phase I/II trial evaluating CoVac-1, which aims for induction of SARS-CoV-2-specific T cells, in patients with congenital or acquired B-cell deficiency (mainly patients with leukemia and lymphoma). Sixty-four percent of the study participants had not developed any humoral immune response after previously receiving approved SARS-CoV-2 vaccines.
The researchers found that CoVac-1 showed a good safety and tolerability profile, with no relevant systemic adverse events, similar to that seen in healthy adults. On day 28 after CoVac-1 application, 93 percent of study participants had CoVac-1-specific T-cell responses; the earliest responses were evidenced at day 14 (71 percent). Multifunctional T-helper 1 CD4+ T cells mediated vaccine-induced T-cell responses. In this population, CoVac-1 induced T cell responses that were similar to those seen in healthy volunteers after natural infection or induced by approved vaccines.
"CoVac-1 is designed to induce broad and long-lasting SARS-CoV-2 T-cell immunity, even in individuals who have impaired ability to mount sufficient immunity from a currently approved vaccine, and thus protect these high-risk patients from a severe course of COVID-19," a coauthor said in a statement.
Several authors disclosed financial ties to the biopharmaceutical industry.
Related Posts
La tasa de mortalidad por la cirrosis hepática alcohólica se triplica en dos décadas en EE. UU.
LUNES, 20 de junio de 2022 (HealthDay News) -- Los estadounidenses quizá tengan...
For Folks Without the Condition, Taking ADHD Meds to Get ‘Smarter’ Could Backfire
WEDNESDAY, June 14, 2023 (HealthDay News) -- So-called “smart drugs” meant to...
Topical Antibiotics Shorten Duration of Conjunctival Symptoms
TUESDAY, Oct. 4, 2022 (HealthDay News) -- For children with acute infective...
Este verano, conozca su riesgo de alergia a picaduras de insectos
LUNES, 19 de junio de 2023 (HealthDay News) -- Si sueña con un verano perfecto,...